Skip to main content
Premium Trial:

Request an Annual Quote

Anagnostics Taps Ramcon to Sell HybCell Array Platform in Nordic Region

Premium

Anagnostics said this week that Ramcon will sell its HybCell tests to customers in Denmark, Finland, Iceland, Norway, and Sweden.

Specifically, Ramcon will offer Anagnostics' drugs of abuse tests. The immunochemical assays rely on urine or saliva samples to semi-quantitatively test for drugs of abuse and psychotropic substances using the firm's cylindrical HybCell array platform. Ramcon will also sell Anagnostics' recently launched compact-sequencing-based pharmacogenetics tests (BAN 10/26/2010).

Anagnostics has expanded its reach via similar partnerships. The St. Valentin, Austria-based firm has inked deals with Cell.Eng to represent it in Italy, Invicon to sell its products in Germany, and Biogenetix to represent it in the Romanian market.

Birkerød-based Ramcon employs 24 sales support and service personnel. The company represents other players in the array market, including French scanner firm Innopsys, Italian biochip maker Silicon Biosystems, and Affymetrix's Panomics business.

Further details of the deal were not discussed.

The Scan

Time to Act

A new report urges the UK to consider regulations to protect against the misuse of genomic technologies, according to the Guardian.

Fulgent Seeking Defamation Suit

Fulgent Genetics says it plans to sue Los Angeles County Sheriff Alex Villanueva for defamation, the Los Angeles Times reports.

Speeding Gene-Edited Crops

Reuters reports that China's new trial rules will make it easier to grow gene-edited crops there.

Nucleic Acids Research Papers on Viral Recombination, Pan-Cancer Mutations, SARS-CoV-2 Variability

In Nucleic Acids Research this week: updated pipeline to detect viral recombination, mutational patterns in tumor samples, and more.